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Magnetic resonance imaging (MRI) was first introduced by Paul Lauterbur in 1973; the same year that Hounsfield
and Ambrose reported on their initial experience with X-ray computed tomography (CT). The subsequent develop-
ment and acceptance of MRI has been slower than that of CT. Recently there has been a dramatic improvement in
MR image quality. MR imagers are now more widely available. Within 16 years CT, which represented such an
enormous advance in diagnostic imaging when introduced in the early 1970s, is beginning to look vulnerable. The
oncologist must now consider whether MR might replace CT.
The advantages of MRI over CT are most obvious when imaging the central nervous system. MRI is more
sensitive than CT to changes in brain morphology and in turn more sensitive to the presence of tumour
(Brant-Zawadski, 1988). The size and extent ofprimary brain tumours may be better appreciated on MRI, especially
when a combination of T2 weighted and gadolinium DTPA contrast enhanced TI (Gd-MR(Tl)) images have been
obtained. Gadolinium DTPA is injected intravenously and is distributed throughout the body in a manner analogous
to that of iodinated contrast injected at CT examination. In the brain gadolinium DTPA will accumulate where the
blood-brain barrier is deficient, and shortens the MR relaxation times directly in proportion to its local concentra-
tion. Tumours that enhance at post-contrast CT examination will also enhance at Gd-MR(TI) examination. The
strengths and limitations of this technique are similar to those already seen at CT. Tumours may enhance strongly,
and tumour may be separated from surrounding oedema or central necrosis. Unfortunately postoperative enhance-
ment may be due to either residual/recurrent tumour, or the direct effect of surgery.
In the assessment ofsupratentorial tumours MRI is better than CT at demonstrating spread of tumour across the
midline via the corpus callosum. T2 weighted MRI may demonstrate low-grade gliomas as areas of abnormal signal
intensity, when the same lesions are invisible on CT as they exert no mass effect, exhibit no enhancement and are not
associated with surrounding oedema. This is a very important diagnostic use of MRI (Pomeranz, 1989). CT in
patients with low grade tumours may show only calcifications. The demonstration of abnormal signal on MRI
examination may confirm the presence of low grade tumour, when questionable calcifications are seen at CT. The
multiplanar capability of MRI is useful in assessing posterior fossa and extra-axial tumours, especially those arising
in the pituitary fossa, neural foramina and dural spaces. Gd-DPTA contrast enhancement is important in the
adequate depiction of these tumours (Berry et al.,1986).
Intracerebral metastases are recognised on CT mainly because of their multiplicity. Gd-DTPA MRI is slightly
better than contrast enhanced CT at demonstrating small metastases. This may be useful particularly in the patient
with an apparently solitary metastasis on CT imaging, who is being considered for local treatment, either resection
or limited field irradiation. The demonstration of an additional lesions(s) would lead to a definite change in
management. Gd-DPTA enhanced MRI may also demonstrate asymptomatic metastases in patients with normal CT
brain scans (Cherryman et al., 1989). Again this is useful if major changes in management would result from the
demonstration of an unsuspected brain metastasis. There is also a suggestion that MR may help in the vexed
question of diagnosing leptomeningeal metastatic disease (Davis et al., 1987).
The spinal cord and its surroundings are an important site of disease spread, and an area often difficult to
adequately image even with a combination of plain radiographs, myelography and CT scanning. MRI adds a new
dimension to the imaging of this area (Haughton, 1988). The multiplanar capability of MR allows the spinal cord to
be visualised in saggital, coronal and axial planes. Intraspinal tumours are recognised because of changes in
morphology and tumour enhancement following Gd-DPTA injection. Extradural masses are easily appreciated and
spinal cord compressions well seen (Williams et al., 1989a). This allows for more appropriate treatment planning.
Coronal MR sections are ideal at demonstrating paravertebral masses, dumbbell tumours and root compressions.
MRI of the spine is the most important application of MRI in present oncological practice.
Outside the CNS MRI is of most value in assessing the soft-tissues. TI weighted MR images are best at
differentiating soft-tissues from fat. T2 weighted images allow the differentiation of normal from abnormal soft-
tissues. This is a major advance on CT, as it is impossible to recognise soft-tissue dense tumour tissue within the
muscles on CT until the shape of the muscle is altered. On T2 weighted MR images tumour spread into muscles may
be visualised, even at an early stage when the muscle remains of normal shape. This is of most use in assessing the
extent of soft-tissue tumours, including the extracranial head and neck. There are some caveats to the use of MRI in
soft-tissue malignancy. First, MR is non-specific and it may not be possible to differentiate tumour from non-
malignant causes of altered signal intensity. Second, the extent of tumours may be over-estimated as peritumoral
oedema may appear of similar signal intensity and be incorrectly interpreted as tumour. MRI may be of value in the
follow-up of tumours treated with chemotherapy and/or radiotherapy. Residual or recurrent tumour activity may be
suspected from persistent or recurrent high T2 signal intensities.
MRI is also of value in assessing bone marrow. Metastatic involvement may be seen before the isotope scan is
abnormal (Williams et al., 1989b). The extent of marrow abnormality as demonstrated at MRI may also exceed that
demonstrated on conventional radiographs, routine marrow aspirates/trephines and even specialised nuclear
medicine techniques, such as mIBG scanning in metastatic neuroblastoma (Olliff et al., 1989). MRI may also be
useful in differentiating vertebral collapse due to osteoporosis from that associated with metastatic disease (Smoker
et al., 1987).
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The combination of sensitivity to marrow disease; spinal cord, root and nerve involvement; and soft tissue
metastasis makes MR a useful tool in the investigation of pain or unexplained neurological change in the cancer
patient. Clinical experience at the Royal Marsden (unpublished data) suggests that this will evolve into a major
application of MR in oncology.
In the USA the impact of MRI on head and neck imaging has been dramatic. In the UK there are fewer MRI
imagers available, and the value of the technique in this area is not widely appreciated. MRI scores over CT because
of superior soft-tissue contrast, multiplanar imaging capability and excellent spatial resolution. Present opinion
would consider MRI the modality of choice in evaluating the nasopharynx, paranasal sinuses, nasal cavity, floor of
the mouth, tongue, oropharynx, parapharyngeal spaces, larynx salivary glands and neck (Som & Shapiro, 1989).
Abnormal lymph nodes may only be recognised on MRI once they have enlarged. Unfortunately MR cannot
determine the cause of nodal enlargement or recognise the presence of nodal micrometastases (Dooms et al., 1985).
In an oncological setting CT examination of the thorax is likely to remain superior to MRI. CT is the definitive
method for the detection of small pulmonary metastases. In the mediastinum there is probably little significant
difference between CT and MR. MR is subject to artifacts arising from respiratory, cardiac and other physiological
movements. Artifacts may also be generated from flow phenomena.
In the abdomen the contribution of MR is also limited by these artifacts. The liver is the easiest organ to image
and the present consensus is that MR of the liver complements CT and US examination. In general it is most cost
effective to progress from simplest to most expensive, i.e. US, CT and only then MR.
MR is a still developing imaging technique, unlike CT which seems at present to have peaked. MR remains a
more difficult examination than CT for both the patient and the radiologist. It is likely that some of the present
difficulties associated with MR will be overcome. The use of MR contrast agents is a new and underexplored field; it
is possible that the use of these agents might improve the specificity of the technique.
In present oncological practice MR of the spinal region and marrow is a revelation and has already altered clinical
practice. MR will replace CT in brain, as well as extracranial head and neck imaging. In the remainder of the body
CT remains supreme. MR is rightly limited to complementing CT examination of the soft-tissues. It is curious that
we needed MR to appreciate just how useful body CT can be.
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